Biohaven Pharma
About Biohaven Pharma
220 articles with Biohaven Pharma
-
Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM™ (Antibody Recruiting Molecule) Platform, in Combination with NK Cell Therapy for the Treatment of Multiple Myeloma
10/27/2021
Biohaven Pharma Holding Company Ltd. (NYSE: BHVN), announced the enrollment of the first patient in a Phase 1a/1b trial in Multiple Myeloma using the ARM, BHV-1100
-
Biohaven Announces Preliminary 3Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment
10/5/2021
Biohaven Pharmaceutical Holding Company Ltd. today announced preliminary net product revenue of NURTEC ODT (rimegepant) for the third quarter of 2021.
-
Biohaven Provides Update On Phase 3 Trial And Multiple System Atrophy (MSA) Program
9/27/2021
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced results from a focused analysis of a clinical trial of verdiperstat in multiple system atrophy (MSA).
-
Biohaven Pharma's latest update on its Phase III clinical trial to use verdiperstat as a potential treatment for multiple system atrophy showed that it did not meet its expected outcomes.
-
Biohaven Spotlights Nurtec® ODT (rimegepant), the only dual-therapy indicated for both the acute and preventive treatment of migraine, at the 2021 International Headache Society - European Headache Federation Joint Congress
9/9/2021
- Biohaven presenting 17 abstracts, including three late-breaking abstracts and four oral presentations, highlighting the efficacy and safety of Nurtec ODT as both an acute and preventive treatment of migraine
-
Biohaven Reports Second Quarter 2021 Financial Results And Recent Business Developments
8/9/2021
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases including rare disorders, reported financial results for the second quarter ended June 30, 2021, and provided a review of recent accomplishments and anticipated upcoming milestones.
-
Biohaven Announces Preliminary 2Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment
7/7/2021
- Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company with a portfolio of innovative, late-stage product candidates, announced preliminary net product revenue of NURTEC ODT for the second quarter of 2021.
-
Photo of Biohaven Pharmaceuticals Ringing the Opening Bell Available on Business Wire's Website and the Associated Press Photo Network
6/8/2021
A photo is available on Business Wire's website and the Associated Press Photo Network of Biohaven Pharmaceuticals ringing the opening bell, June 8, 2021.
-
Biohaven Showcases 19 Presentations at the 2021 Virtual Annual Scientific Meeting of the American Headache Society
6/3/2021
- Nurtec ODT now the first and only medication for both acute and preventive treatment - New and encore clinical data presentations highlight the efficacy and safety of Nurtec ODT as both acute treatment of migraine and preventive treatment of episodic migraine
-
A platform trial is also efficient in that it enables the investigators to share placebo information.
-
Biohaven's Nurtec® ODT Signs as Primary Partner with Rick Ware Racing for 2021 NTT INDYCAR Series Program
5/14/2021
Biohaven Pharmaceuticals announced that Nurtec® ODT will be the primary partner for the Rick Ware Racing No. 51 NTT IndyCar Series program.
-
National Headache Foundation Survey Shows Majority of People with Migraine are Unable to Control Disease and Dissatisfied with Current Preventive Treatment Options
5/11/2021
The National Headache Foundation announced findings from a new survey, Preventing Migraine Attacks: A Current Perspective, which characterizes the experiences of people living with migraine and highlights the physical and emotional barriers to preventive treatment.
-
Biohaven Reports First Quarter 2021 Financial Results and Recent Business Developments
5/10/2021
- Exceeded expectations of NURTEC™ ODT (rimegepant) with net product revenue of $43.8 million for the first quarter of 2021, totaling $107.4 million in net product revenue since launch in March 2020
-
Biohaven to Report First Quarter 2021 Financial Results and Recent Business Developments on May 10, 2021
4/28/2021
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, will hold its upcoming first quarter 2021 earnings call and webcast, reporting financial results
-
AAN Annual Meeting Highlights: Sleep Quality, Migraine, COVID-19 Interferon Treatment and More
4/21/2021
The American Academy of Neurology Virtual Annual Meeting 2021 is ongoing from April 17 through 22, with literally hundreds of presentations. Here’s a peek at just some of them. -
Biohaven Highlights Neuroscience Advancements with 22 Presentations at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting
4/13/2021
- Pivotal trial of rimegepant for the preventive treatment of migraine spotlights reduction of 4.3 monthly migraine days during weeks 9-12 and rapid onset of preventive effects observed within the first week of treatment - Post-hoc analysis of rimegepant in the acute treatment of migraine dosed on an as needed (p.r.n.) basis demonstrated clinically relevant reductions in monthly migraine days over time
-
Biohaven Announces Preliminary 1Q2021 Net Product Revenue For NURTEC ODT
4/7/2021
- NURTEC® ODT achieved preliminary net product revenue of approximately $43.8 million for the first quarter of 2021 - Launch to date net product revenue for NURTEC ODT is approximately $107.4 million, with over 500,000 prescriptions filled since launch in March 2020
-
Biohaven Enrolls First Patient in Phase 2/3 Trial of Oral Zavegepant, Prompting $100 Million Milestone Funding Payment from Royalty Pharma
3/29/2021
-- Zavegepant is a high affinity, selective and structurally unique, third generation, CGRP receptor antagonist in development for both migraine and non-migraine CGRP-mediated diseases -- Biohaven and Royalty Pharma have previously announced a funding agreement to advance the clinical development of intranasal and oral formulations of zavegepant
-
Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares - Mar 16, 2021
3/16/2021
Biohaven Pharmaceutical Holding Company Ltd., a commercial–stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative, late–stage product candidates targeting neurological diseases, including rare disorders, announced the pricing of its underwritten public offering of 2,686,409 of its common shares at a price to the public of $76.00 per share.
-
Biohaven Announces Proposed Public Offering Of Common Shares - Mar 15, 2021
3/15/2021
Biohaven Pharmaceutical Holding Company Ltd., a commercial-stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative, late–stage product candidates targeting neurological diseases, including rare disorders, announced that it has commenced an underwritten public offering of $200 million of its common shares.